Twitter

Chordate Medical exhibits at the European Headache Congress in Barcelona

Chordate Medical’s CEO, Anders Weilandt, and CSO, Jan Hermansson, will participate and exhibit at the European Headache Congress from December 6 to 9 alongside Chordate’s Italian distributor, Vedise Hospital S.p.A. Chordate will present Ozilia and share the case study from the migraine study PM007.

“EHC is one of the largest gatherings for physicians and professionals in the headache field in general, and the migraine sector in particular. We anticipate a significant number of Italian delegates at the congress, and Vedise can address inquiries about Ozilia,” says Anders Weilandt.

european headache congress

The theme of the 2023 European Headache Congress is “Headache: Expanding the horizon,” and over the four days of the congress, the latest developments and innovations in the headache field will be highlighted. In addition to Italy, delegates from other important European markets for Chordate.

“This is another opportunity for us to raise awareness about Ozilia. We have participated in several congresses in recent months, and the interest in Ozilia has been substantial,” says Anders Weilandt.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter